Anti–tumour necrosis factor-α therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study
Article first published online: 14 NOV 2007
© 2007 The Authors
Journal of the European Academy of Dermatology and Venereology
Volume 22, Issue 3, pages 341–344, March 2008
How to Cite
Gisondi, P., Cotena, C., Tessari, G. and Girolomoni, G. (2008), Anti–tumour necrosis factor-α therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. Journal of the European Academy of Dermatology and Venereology, 22: 341–344. doi: 10.1111/j.1468-3083.2007.02429.x
- Issue published online: 14 NOV 2007
- Article first published online: 14 NOV 2007
- Received: 16 April 2007, accepted 26 June 2007; DOI: 10.1111/j.1468-3083.2007.02429.x
- anti-TNF-alpha therapy;
- body weight;
- chronic plaque psoriasis
Background Chronic plaque psoriasis is associated with overweight or obesity. Anti–tumour necrosis factor-α (anti-TNF-α) treatments are now frequently used in psoriasis management. TNF-α is deeply involved in body weight homeostasis, which may be affected by TNF-α–targeted therapy.
Objective To investigate whether anti-TNF-α treatments is associated with changes in body weight in patients with chronic plaque psoriasis.
Methods We performed a retrospective controlled analysis comparing the variations in body weight and body mass index (BMI) in three closed cohorts of psoriatic patients during a 6-month treatment with etanercept (N = 58), infliximab (N = 40) or methotrexate (N = 43).
Results We observed a body weight increment of 1.5 ± 2.7 kg (mean ± SD; P = 0.0002) and 2.5 ± 3.3 kg (P = 0.004) in patients treated with etanercept and infliximab, respectively. In contrast, a non-significant change (0.6 ± 1.4 kg; P = 0.4) was measured in patients treated with methotrexate. The BMI increased with 0.5 ± 0.5 (P = 0.01) and 0.8 ± 1 (P = 0.003) points in patients treated with etanercept and infliximab, respectively, whereas it did not change (< 0.2 ± 0.5; P = 0.06) in patients treated with methotrexate. About one fourth of patients experienced a 4- to 10-kg weight gain. Differences in body weight variations among patients treated with anti-TNF-α therapies and methotrexate were statistically significant (P = 0.0005). We could not identify clinical parameters predicting this phenomenon.
Conclusions Patients with psoriasis treated with long-term anti-TNF-α therapies may manifest a body weight gain. This effect should be taken into account in the global approach to patients with psoriasis.